Peter Clark, MA, MD, FRCP: A Payer Perspective

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Dec

Today In Oncology

Peter Clark, MA, MD, FRCP: A Payer Perspective

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL

GLP-1 RAs May Have Little or No Effect on the Risk of Obesity-Related Cancers

Deb Schrag Elected 2027–2028 ASCO President

NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer

Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns